NEW YORK, Oct 17 (Reuters) - Merck & Co said on Wednesday U.S. regulators have approved use of its Januvia diabetes drug in new combinations with other treatments, but noted reports of serious ...

Morgan Stanley raised earnings forecasts on Merck and expects the pharmaceutical firm's sales of Januvia, a new diabetes treatment, to come in higher than current expectations. Recent comments by Dr.

Just eight days after posting a trial win over Merck diabetes stalwart Januvia, Novo Nordisk candidate semaglutide is back with another. Thursday, the Danish drugmaker said that in a phase 3a trial, ...

Once it wins approval, Novo Nordisk’s highly anticipated oral diabetes drug semaglutide will go up against some stiff competition. But the drugmaker just showed that its up-and-comer can take the heat ...

In terms of controlling Type 2 diabetes and potentially obesity, Boston’s Intarcia Therapeutics just released some impressive Phase 3 findings: Its implantable device has been found to be more ...

> It's a big week for Merck, which is hoping to move two blockbusters--Gardasil and Januvia--past important milestones. Article > Pfizer won a landmark patent protection case in China, signaling the ...

Type II diabetes costs the NHS £8.8 billion a year. Novo Nordisk has announced that its oral semaglutide improved glycaemic control in people with type II diabetes across baseline HbA1c levels in the ...

Januvia (sitagliptin) is a prescription drug that’s used to treat type 2 diabetes in adults. The drug comes as an oral tablet. It’s usually taken once per day. Januvia is used in adults to treat type ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dear Dr. Roach • Is Januvia an effective drug for diabetes? What are the side effects? — M.A.A. Answer • Sitagliptin (Januvia) is ...